Sarah M. Trinder
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sarah M. Trinder has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Rishi S. Kotecha
Department of Clinical Haematology, Oncology, Blood and Marrow Transplantation Perth Children's Hospital Perth Western Australia Australia
2 shared publications A. Charles
Department of Anatomical Pathology Perth Children's Hospital Nedlands Western Australia Australia
1 shared publication- Andrew C. Wood
Blood and Cancer Centre Starship Children's Hospital Auckland New Zealand
1 shared publication - Andrew S. Moore
Oncology Service, Children’s Health Queensland Hospital and Health Service, Brisbane, Australia
1 shared publication - Anne L. Ryan
Department of Paediatric and Adolescent Oncology and Haematology, Perth Children’s Hospital, Nedlands, WA, Australia
1 shared publication - Bryony Ross
The Children's Cancer and Haematology Service John Hunter Children's Hospital Newcastle New South Wales Australia
1 shared publication
Latest Publications
- Open Access
- 10 August 2026
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 62 (10) , 1913-1920
Optimising Asparaginase Use and Managing Hypersensitivity in A ustralasia—A Clinical Practice Guideline From the A ustralian and N ew Z ealand Children's Haematology/Oncology Group
Background: Asparaginase is a critical component of modern multi‐agent chemotherapy regimens for paediatric acute lymphoblastic leukaemia and lymphoblastic lymphoma, with inadequate exposure leading to inferior patient outcomes. Objectives: To develop a clinical practice guideline for the use of asparaginase products in the Australasian context. Methods: This clinical practice guideline was developed following consultation and a review of the available published data and is designed to standardise treatment across the region. Results: This paper reports the position of the Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG) on key areas including established and new asparaginase products and their use in Australasia, monitoring and interpretation of serum asparaginase activity, care in the setting of hypersensitivity and management of suboptimal asparagine depletion. Conclusions: This clinical practice guideline will assist clinicians in the Australasian region who provide care to children, adolescents and young adults receiving asparaginase therapy.
- 10 August 2026
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 62 (10) , 1913-1920
Open AccessOptimising Asparaginase Use and Managing Hypersensitivity in A ustralasia—A Clinical Practice Guideline From the A ustralian and N ew Z ealand Children's Haematology/Oncology Group
Background: Asparaginase is a critical component of modern multi‐agent chemotherapy regimens for paediatric acute lymphoblastic leukaemia and lymphoblastic lymphoma, with inadequate exposure leading to inferior patient outcomes. Objectives: To develop a clinical practice guideline for the use of asparaginase products in the Australasian context. Methods: This clinical practice guideline was developed following consultation and a review of the available published data and is designed to standardise treatment across the region. Results: This paper reports the position of the Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG) on key areas including established and new asparaginase products and their use in Australasia, monitoring and interpretation of serum asparaginase activity, care in the setting of hypersensitivity and management of suboptimal asparagine depletion. Conclusions: This clinical practice guideline will assist clinicians in the Australasian region who provide care to children, adolescents and young adults receiving asparaginase therapy.
- Open Access
- 30 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Pediatrics
- Vol. 2 (1)
Metastatic meningioma in childhood and adolescence
Metastatic meningioma in childhood and adolescence is an extremely rare entity, with limited available data. We sought to characterize features, treatment and outcomes by performing a systematic review of all cases of metastatic meningioma diagnosed before 18 years of age published since 1989. We found metastases predominantly occurred in patients with grade 2 and 3 tumors and in the context of local relapse. Most metastatic sites were extracranial, with lung/pleura the dominant extracranial site. The remainder occurred at distant sites within the central nervous system. We propose that screening of these sites should be considered if relapse is suspected.
- 30 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Pediatrics
- Vol. 2 (1)
Open AccessMetastatic meningioma in childhood and adolescence
Metastatic meningioma in childhood and adolescence is an extremely rare entity, with limited available data. We sought to characterize features, treatment and outcomes by performing a systematic review of all cases of metastatic meningioma diagnosed before 18 years of age published since 1989. We found metastases predominantly occurred in patients with grade 2 and 3 tumors and in the context of local relapse. Most metastatic sites were extracranial, with lung/pleura the dominant extracranial site. The remainder occurred at distant sites within the central nervous system. We propose that screening of these sites should be considered if relapse is suspected.
- Open Access
- 27 September 2025
- Published by Springer Nature in Targeted Oncology
- Vol. 20 (6) , 907-915
From Sequencing to Survival: The Growing Role of Precision Medicine in Paediatric Oncology
The advent of comprehensive genomic sequencing has catalysed the emergence of paediatric precision medicine platforms globally. These have established the feasibility of profiling tumours at scale, enhancing our understanding of the genetic landscape of paediatric tumours and enabling identification of driver mutations and actionable targets. In turn, this has created the opportunity for development of novel precision-guided therapies (PGT). This commentary synthesizes evidence from major collaborative trials with a focus on outcome reporting, particularly in the relapsed/refractory and high-risk patient cohorts. Patients receiving PGT in these cohorts demonstrate meaningful responses and survival benefit, particularly when treatment is based on high-level clinical evidence and administered early in the disease course. However, challenges remain in addressing low uptake of PGT, likely hindered by substantial barriers in access and complex pharmaceutical regulatory constraints. Furthermore, heterogeneity in recommendation and outcome reporting hinders data harmonisation and generalisability of results. In addition to improving outcomes, comprehensive profiling can contribute to diagnostic refinement and identification of germline variant detection in a subset of patients. Emerging studies, conducted through national initiatives, signify the potential benefit of precision medicine for all patients with childhood cancer regardless of risk. A dynamic approach to address challenges and ensure cost–benefit is necessary to embed precision oncology as a standard of care for all children with cancer.
- 27 September 2025
- Published by Springer Nature in Targeted Oncology
- Vol. 20 (6) , 907-915
Open AccessFrom Sequencing to Survival: The Growing Role of Precision Medicine in Paediatric Oncology
The advent of comprehensive genomic sequencing has catalysed the emergence of paediatric precision medicine platforms globally. These have established the feasibility of profiling tumours at scale, enhancing our understanding of the genetic landscape of paediatric tumours and enabling identification of driver mutations and actionable targets. In turn, this has created the opportunity for development of novel precision-guided therapies (PGT). This commentary synthesizes evidence from major collaborative trials with a focus on outcome reporting, particularly in the relapsed/refractory and high-risk patient cohorts. Patients receiving PGT in these cohorts demonstrate meaningful responses and survival benefit, particularly when treatment is based on high-level clinical evidence and administered early in the disease course. However, challenges remain in addressing low uptake of PGT, likely hindered by substantial barriers in access and complex pharmaceutical regulatory constraints. Furthermore, heterogeneity in recommendation and outcome reporting hinders data harmonisation and generalisability of results. In addition to improving outcomes, comprehensive profiling can contribute to diagnostic refinement and identification of germline variant detection in a subset of patients. Emerging studies, conducted through national initiatives, signify the potential benefit of precision medicine for all patients with childhood cancer regardless of risk. A dynamic approach to address challenges and ensure cost–benefit is necessary to embed precision oncology as a standard of care for all children with cancer.
- 3 March 2025
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 61 (6) , 836-845
Renal Masses in Childhood: An Australian Perspective
Childhood renal masses comprise a heterogeneous group of conditions that have a wide range of presentations. This review outlines an approach to the diagnostic work‐up of childhood renal masses and discusses the most common presentations and treatments. Renal tumours make up 5% of childhood cancer in Australia, with Wilms tumour being the most common under age 10 years. Significant advances have been made through global cooperative efforts to improve the understanding of biology, genetic basis, and classification of disease as well as standardise treatment protocols. As survival outcomes have improved, a focus on surveillance of the late effects of treatment is important. Around 10%–15% are related to cancer predisposition syndromes, and therefore consideration of this is critical at diagnosis and throughout care. Early involvement of a multi‐disciplinary team is essential to ensure accurate diagnosis and management for these children and their families. Australia holds a unique perspective, as both European (SIOP) and North American (COG) treatment approaches are adopted across its paediatric oncology centres for malignant tumours. This results in flexibility in patient management but also necessitates careful decision‐making regarding protocol selection.
- 3 March 2025
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 61 (6) , 836-845
Renal Masses in Childhood: An Australian Perspective
Childhood renal masses comprise a heterogeneous group of conditions that have a wide range of presentations. This review outlines an approach to the diagnostic work‐up of childhood renal masses and discusses the most common presentations and treatments. Renal tumours make up 5% of childhood cancer in Australia, with Wilms tumour being the most common under age 10 years. Significant advances have been made through global cooperative efforts to improve the understanding of biology, genetic basis, and classification of disease as well as standardise treatment protocols. As survival outcomes have improved, a focus on surveillance of the late effects of treatment is important. Around 10%–15% are related to cancer predisposition syndromes, and therefore consideration of this is critical at diagnosis and throughout care. Early involvement of a multi‐disciplinary team is essential to ensure accurate diagnosis and management for these children and their families. Australia holds a unique perspective, as both European (SIOP) and North American (COG) treatment approaches are adopted across its paediatric oncology centres for malignant tumours. This results in flexibility in patient management but also necessitates careful decision‐making regarding protocol selection.
- 27 December 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (3) , e30841
Fatal tumor lysis syndrome in a pediatric patient with acute lymphoblastic leukemia treated with venetoclax
- 27 December 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (3) , e30841
Fatal tumor lysis syndrome in a pediatric patient with acute lymphoblastic leukemia treated with venetoclax